Japanese Prefectures Struggle To Meet New Goals Of Flu Drug Stockpiles
This article was originally published in PharmAsia News
Nearly a third of Japan's 47 prefectures have increased their stock of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) to treat H1N1 flu cases should they occur. The 15 are stepping up their stockpiling of the drugs to meet a national government target of being able to treat as much as 45 percent of the population. A survey shows the stockpiling success varies widely by prefecture, with some nearly complete and others still struggling. The Japanese system calls for the central government to obtain half the drugs and each prefecture to acquire the other half. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.